N	Concordance
1	ed that the opioid component of [3H]Met-enkephalin-Arg6-Phe7 recognition site ar
2	dopaminergic pathway on substance P and enkephalin mRNA expression in the rat ne
3	omega-diamino acid residues. The cyclic enkephalin analogue containing a 21-memb
4	a statistically significant increase in enkephalin-positive cells in involved ps
5	results indicate that both met- and leu-enkephalin increase the activity of the 
6	m, or were preperfused with D-Ala2-Leu5-enkephalin or D-pen2,5-enkephalin, a-del
7	hitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopept
8	ver, did not inhibit the release of Met-enkephalin induced by intraventricularly
9	n was depressed by application of [Met5]enkephalin in a dose dependent manner. T
10	tion of RB 101, a complete inhibitor of enkephalin catabolism, has been reported
11	mponent of the nociceptin modulation of enkephalin release is mediated via opioi
12	 might be involved in the regulation of enkephalin expression in the striatum, a
13	torphine, and [D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin increased potassium conductan
14	ncubation. The receptor affinity of the enkephalin derivatives became significan